PDF下载 ( 1966 KB)
肝硬化患者非肿瘤性门静脉血栓形成的早期预测因子
DOI: 10.3969/j.issn.1001-5256.2022.09.039
利益冲突声明：所有作者均声明不存在利益冲突。
作者贡献声明：周遵兰负责选题，收集分析资料，撰写文章; 杨丽娜、李清清参与收集资料，修改论文; 王红负责拟定写作思路，指导撰写文章，提供修改意见并最终定稿。
Research advances in the early predictive factors for non-neoplastic portal vein thrombosis in liver cirrhosis
-
摘要: 门静脉血栓形成(PVT)是肝硬化失代偿期患者常见的并发症之一，包括非肿瘤性PVT和出现原发性肝癌后并发门静脉瘤栓，其后果可导致肝功能恶化、加重食管胃底静脉曲张出血等相关门静脉高压不良事件，降低肝移植术后患者的生存率，严重者可能危及生命。因此，对PVT的危险因素及早期预测因子作进一步研究，具有重要的临床意义。本文拟从传统的血栓形成三要素及肝功能损伤严重程度、食管胃底静脉曲张内镜下治疗等方面，对近年来肝硬化非肿瘤性PVT早期预测因子进行阐述。对相关研究分析表明，部分早期预测因子与PVT具有明确的相关性，为PVT的早期识别提供帮助。但具体预测值可能存在差异，需要多中心、前瞻性研究证实。Abstract: Portal vein thrombosis (PVT) is one of the common complications in patients with decompensated liver cirrhosis, including non-neoplastic PVT and portal vein tumor thrombus after the onset of primary liver cancer. It can lead to the deterioration of liver function, aggravate the portal hypertension-related adverse events including esophagogastric variceal bleeding, reduce the survival rate of patients after liver transplantation, and even threaten the life of patients in severe cases. Therefore, it is of great clinical significance to further explore the risk factors and early predictive factors for PVT. This article elaborates on the recent advances in the early predictive factors for non-neoplastic PVT in liver cirrhosis from the aspects of the three elements of thrombosis, the severity of liver injury, and the endoscopic treatment of esophagogastric varices. The analysis of related research shows that some early predictive factors are clearly associated with the formation of PVT, which provides help for the early identification of PVT; however, specific predictive values may be unclear or have certain differences, which needs to be confirmed by multicenter prospective studies.
-
Key words:
- Liver Cirrhosis /
- Venous Thrombosis /
- Risk Factors
-
[1] BHANGUI P, LIM C, LEVESQUE E, et al. Novel classification of non-malignant portal vein thrombosis: A guide to surgical decision-making during liver transplantation[J]. J Hepatol, 2019, 71(5): 1038-1050. DOI: 10.1016/j.jhep.2019.08.012. [2] TURON F, DRIEVER EG, BAIGES A, et al. Predicting portal thrombosis in cirrhosis: A prospective study of clinical, ultrasonographic and hemostatic factors[J]. J Hepatol, 2021, 75(6): 1367-1376. DOI: 10.1016/j.jhep.2021.07.020. [3] FRANCOZ C, VALLA D, DURAND F. Portal vein thrombosis, cirrhosis, and liver transplantation[J]. J Hepatol, 2012, 57(1): 203-212. DOI: 10.1016/j.jhep.2011.12.034. [4] TAO YF, TENG F, WANG ZX, et al. Liver transplant recipients with portal vein thrombosis: a single center retrospective study[J]. Hepatobiliary Pancreat Dis Int, 2009, 8(1): 34-39. http://www.hbpdint.com/CN/article/downloadArticleFile.do?attachType=PDF&id=3109 [5] DONG G, HUANG X, JIANG S, et al. Simvastatin mitigates apoptosis and transforming growth factor-beta upregulation in stretch-induced endothelial cells[J]. Oxid Med Cell Longev, 2019, 2019: 6026051. DOI: 10.1155/2019/6026051. [6] ZOCCO MA, DI STASIO E, DE CRISTOFARO R, et al. Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development[J]. J Hepatol, 2009, 51(4): 682-689. DOI: 10.1016/j.jhep.2009.03.013. [7] STINE JG, WANG J, SHAH PM, et al. Decreased portal vein velocity is predictive of the development of portal vein thrombosis: A matched case-control study[J]. Liver Int, 2018, 38(1): 94-101. DOI: 10.1111/liv.13500. [8] MARUYAMA H, OKUGAWA H, TAKAHASHI M, et al. De novo portal vein thrombosis in virus-related cirrhosis: predictive factors and long-term outcomes[J]. Am J Gastroenterol, 2013, 108(4): 568-574. DOI: 10.1038/ajg.2012.452. [9] DONG G, HUANG XQ, ZHU YL, et al. Increased portal vein diameter is predictive of portal vein thrombosis development in patients with liver cirrhosis[J]. Ann Transl Med, 2021, 9(4): 289. DOI: 10.21037/atm-20-4912. [10] ZHANG Y, WEN TF, YAN LN, et al. Preoperative predictors of portal vein thrombosis after splenectomy with periesophagogastric devascularization[J]. World J Gastroenterol, 2012, 18(15): 1834-1839. DOI: 10.3748/wjg.v18.i15.1834. [11] HUANG L, YU Q, PENG H. Hemorheological alteration in patients with cirrhosis clinically diagnosed with portal vein system thrombosis after splenectomy[J]. Med Sci Monit, 2021, 27: e931157. DOI: 10.12659/MSM.931157. [12] AUSTIN SK, LAMBERT JR. The JAK2 V617F mutation and thrombosis[J]. Br J Haematol, 2008, 143(3): 307-320. DOI: 10.1111/j.1365-2141.2008.07258.x. [13] RABIE H, OTHMAN W, ELSABAAWY DM, et al. Janus Kinase-2 mutation associated portal vein thrombosis complicating liver cirrhosis and hepatocellular carcinoma[J]. Asian Pac J Cancer Prev, 2021, 22(1): 267-275. DOI: 10.31557/APJCP.2021.22.1.267. [14] GAMEIRO AF, ROBALO NUNES A, GUERRA P, et al. Portal vein thrombosis secondary to occult polycythemia vera[J]. Eur J Case Rep Intern Med, 2020, 7(12): 002003. DOI: 10.12890/2020_002003. [15] SAUGEL B, LEE M, FEICHTINGER S, et al. Thrombophilic factor analysis in cirrhotic patients with portal vein thrombosis[J]. J Thromb Thrombolysis, 2015, 40(1): 54-60. DOI: 10.1007/s11239-014-1124-z. [16] AMITRANO L, BRANCACCIO V, GUARDASCIONE MA, et al. Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis[J]. Hepatology, 2000, 31(2): 345-348. DOI: 10.1002/hep.510310213. [17] XIONG JP, PENG YY, ZHANG YX. Differential protein screening in patients with liver cirrhosis complicated with portal vein thrombosis [J]. J Clin Hepatol, 2018, 34(1): 112-117. DOI: 10.3969/j.issn.1001-5256.2018.01.023.熊静平, 彭媛媛, 张跃新. 肝硬化合并门静脉血栓患者的差异蛋白筛选[J]. 临床肝胆病杂志, 2018, 34(1): 112-117. DOI: 10.3969/j.issn.1001-5256.2018.01.023. [18] QUECK A, CARNEVALE R, USCHNER FE, et al. Role of portal venous platelet activation in patients with decompensated cirrhosis and TIPS[J]. Gut, 2020, 69(8): 1535-1536. DOI: 10.1136/gutjnl-2019-319044. [19] MEI B, ZHENG K, CHEN XP. The relationship between portal vein thrombosis and platelet membrane protein CD62P after devascularization[J]. Acta Med Univ Sci Technol Huazhong, 2006, 35(4): 548-549, 552. DOI: 10.3870/j.issn.1672-0741.2006.04.037.梅斌, 郑凯, 陈孝平. 断流术后门静脉血栓形成与血小板膜蛋白CD62P的关系[J]. 华中科技大学学报(医学版), 2006, 35(4): 548-549, 552. DOI: 10.3870/j.issn.1672-0741.2006.04.037. [20] LIN WY, LU X, FAN FJ, et al. Predictive effect of mean platelet volume in patients with portal vein thrombosis: a Meta-analysis of case-control studies[J]. Curr Med Sci, 2018, 38(4): 575-581. DOI: 10.1007/s11596-018-1916-z. [21] FIMOGNARI FL, de SANTIS A, PICCHERI C, et al. Evaluation of D-dimer and factor Ⅷ in cirrhotic patients with asymptomatic portal venous thrombosis[J]. J Lab Clin Med, 2005, 146(4): 238-243. DOI: 10.1016/j.lab.2005.06.003. [22] WEI Y, CHEN X, SHEN H, et al. P-selectin level at first and third day after portal hypertensive splenectomy for early prediction of portal vein thrombosis in patients with cirrhosis[J]. Clin Appl Thromb Hemost, 2018, 24(9_suppl): 76S-83S. DOI: 10.1177/1076029618788180. [23] FEI Y, ZONG GQ, CHEN J, et al. Evaluation of the value of D-dimer, P-selectin, and platelet count for prediction of portal vein thrombosis after devascularization[J]. Clin Appl Thromb Hemost, 2016, 22(5): 471-475. DOI: 10.1177/1076029615569273. [24] LIU RH, LIAN HL. Early predictive value of P-selectin and D-dimer for portal vein thrombosis in cirrhosis[J]. Chin J Thromb Hemost, 2021, 27(6): 974-976. DOI: 10.3969/j.issn.1009-6213.2021.06.031.刘瑞红, 廉恒丽. P-选择素和D二聚体对肝硬化门静脉血栓形成的早期预测价值[J]. 血栓与止血学, 2021, 27(6): 974-976. DOI: 10.3969/j.issn.1009-6213.2021.06.031. [25] ZHANG D, HAO J, YANG N. Protein C and D-dimer are related to portal vein thrombosis in patients with liver cirrhosis[J]. J Gastroenterol Hepatol, 2010, 25(1): 116-121. DOI: 10.1111/j.1440-1746.2009.05921.x. [26] VIOLI F, FERRO D, BASILI S, et al. Ongoing prothrombotic state in the portal circulation of cirrhotic patients[J]. Thromb Haemost, 1997, 77(1): 44-47. DOI: 10.1055/s-0038-1655904 [27] YAO YH, LUO Y, ZHU JL, et al. Measurement and clinical significance of peripheral blood vascular endothelial growth factor in patients with liver cirrhosis and portal vein thrombosis[J]. J Clin Hepatol, 2020, 36(9): 1966-1969. DOI: 10.3969/j.issn.1001-5256.2020.09.011.姚运海, 罗艳, 朱京乐, 等. 肝硬化合并门静脉血栓患者外周血血管内皮生长因子的检测及意义[J]. 临床肝胆病杂志, 2020, 36(9): 1966-1969. DOI: 10.3969/j.issn.1001-5256.2020.09.011. [28] SAMANT H, ASAFO-AGYEI KO, GARFIELD K. Portal vein thrombosis[M]. Treasure Island (FL): StatPearls Publishing, 2021. [29] HAN JB, SHU QH, ZHANG YF, et al. Predictive value of inflammation biomarkers in patients with portal vein thrombosis[J]. J Clin Transl Hepatol, 2021, 9(3): 384-391. DOI: 10.14218/JCTH.2020.00159. [30] PRAKTIKNJO M, TREBICKA J, CARNEVALE R, et al. Von willebrand and factor Ⅷ portosystemic circulation gradient in cirrhosis: implications for portal vein thrombosis[J]. Clin Transl Gastroenterol, 2020, 11(2): e00123. DOI: 10.14309/ctg.0000000000000123. [31] NERY F, CARNEIRO P, CORREIA S, et al. Systemic inflammation as a risk factor for portal vein thrombosis in cirrhosis: a prospective longitudinal study[J]. Eur J Gastroenterol Hepatol, 2021, 33(Suppl 1): e108-e113. DOI: 10.1097/MEG.0000000000001982. [32] HUANG X, FAN X, ZHANG R, et al. Systemic inflammation and portal vein thrombosis in cirrhotic patients with gastroesophageal varices[J]. Eur J Gastroenterol Hepatol, 2020, 32(3): 401-405. DOI: 10.1097/MEG.0000000000001526. [33] SONZOGNI A, PREVITALI G, SEGHEZZI M, et al. Liver histopathology in severe COVID 19 respiratory failure is suggestive of vascular alterations[J]. Liver Int, 2020, 40(9): 2110-2116. DOI: 10.1111/liv.14601. [34] KHEYRANDISH S, RASTGAR A, ARAB-ZOZANI M, et al. Portal vein thrombosis might develop by COVID-19 infection or vaccination: a systematic review of case-report studies[J]. Front Med (Lausanne), 2021, 8: 794599. DOI: 10.3389/fmed.2021.794599. [35] DÍAZ LA, IDALSOAGA F, CANNISTRA M, et al. High prevalence of hepatic steatosis and vascular thrombosis in COVID-19: A systematic review and meta-analysis of autopsy data[J]. World J Gastroenterol, 2020, 26(48): 7693-7706. DOI: 10.3748/wjg.v26.i48.7693. [36] LI L, LU SX, CUI CX, et al. Analysis of risk factors for portal vein thrombosis in 591 patients with liver cirrhosis[J]. Fudan Univ J Med Sci, 2017, 44(3): 288-293. DOI: 10.3969/j.issn.1672-8467.2017.03.006.李玲, 陆申新, 崔春晓, 等. 591例肝硬化患者门静脉血栓形成的危险因素分析[J]. 复旦学报(医学版), 2017, 44(3): 288-293. DOI: 10.3969/j.issn.1672-8467.2017.03.006. [37] MALINCHOC M, KAMATH PS, GORDON FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts[J]. Hepatology, 2000, 31(4): 864-871. DOI: 10.1053/he.2000.5852. [38] GÎRLEANU I, TRIFAN A, COJOCARIU C, et al. The risk of thrombotic events in patients with liver cirrhosis[J]. Rev Med Chir Soc Med Nat Iasi, 2012, 116(4): 991-996. http://www.revmedchir.ro/uploads/1/5/7/2/15722076/8_c_31_girleanu_i_mip_ao_991-996.pdf [39] LIU YZ, SUN YN, LI P, et al. Study of influence factors the prognosis of esophageal variceal sclerosis in patients with cirrhosis[J]. Chin Med Herald, 2021, 18(22): 109-112. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202122025.htm刘远志, 孙亚男, 李鹏, 等. 肝硬化患者食管静脉曲张硬化治疗术预后的影响因素研究[J]. 中国医药导报, 2021, 18(22): 109-112. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202122025.htm [40] LI LJ, WANG S, WEN ZF, et al. Analysis of risk factors for portal vein thrombosis after gastric varices tissue adhesive injection[J]. J Sun Yat-Sen Univ(Medical Sciences), 2015, 36(6): 936-942. DOI: 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2015.0153.李雷佳, 王省, 文卓夫, 等. 胃底静脉曲张组织黏合剂注射术后门静脉血栓形成的危险因素分析[J]. 中山大学学报(医学科学版), 2015, 36(6): 936-942. DOI: 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2015.0153. [41] SHEN DJ, QIAN XX, WANG J, et al. Analysis of risk factors for postoperative non-acute symptomatic portal vein thrombosis after endoscopic gastric varices injection [J]. J Chin Physician, 2021, 23(3): 338-342. DOI: 10.3760/cma.j.cn431274-20210129-00140.沈丹杰, 钱孝先, 王剑, 等. 内镜下胃底静脉曲张注射治疗术后非急性症状性门静脉血栓形成的危险因素分析[J]. 中国医师杂志, 2021, 23(3): 338-342. DOI: 10.3760/cma.j.cn431274-20210129-00140. [42] GABALLA D, BEZINOVER D, KADRY Z, et al. Development of a model to predict portal vein thrombosis in liver transplant candidates: the portal vein thrombosis risk index[J]. Liver Transpl, 2019, 25(12): 1747-1755. DOI: 10.1002/lt.25630. -
本文二维码
计量
- 文章访问数: 293
- HTML全文浏览量: 113
- PDF下载量: 34
- 被引次数: 0
下载:
